David is Chair of Oxular and has more than 30 years of experience in various leadership roles within the ophthalmic pharmaceutical industry. He was previously CEO of Nightstar Therapeutics, a private biopharmaceutical company specialising in developing ocular gene therapies for patients with inherited retinal dystrophies, with David leading the company through a successful NASDAQ listing and M&A transaction. He was previously Vice President of Johnson & Johnson’s Vision Care Franchise, and, prior to that, held several roles at Allergan for 25 years, including Regional President. He is also a Board member of the Glaucoma Foundation.
